Amgen Inc.
NASDAQ:AMGNDrug Manufacturers - General
-$6.93 today
- Market cap
- $240.11B
- Beta
- 0.42
- P/E (TTM)
- 23.2
- EPS (TTM)
- $14.44
- Dividend yield
- 2.93%
Volume 2.58M
Average 2.76M
AMGN Total Liabilities
Everything the company owes to creditors and other parties.
Amgen Inc.NASDAQ: AMGN
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 4.3% from a year ago
Total liabilities stood at $83.95B at the end of Q2 FY2026, up 4.3% from a year earlier and up 0.8% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Total liabilities amounted to 87.8% of total assets at the end of Q2 FY2026, down 3.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +4.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 81.93B USD
- Year-over-year change
- -4.7%
- 4-year CAGR
- +10.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.93B | -4.7% |
| FY2024 | 2024-12-31 | 85.96B | -5.5% |
| FY2023 | 2023-12-31 | 90.92B | +47.9% |
| FY2022 | 2022-12-31 | 61.46B | +12.8% |
| FY2021 | 2021-12-31 | 54.47B | — |
Total Liabilities vs competitors
How AMGN compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4.3% is the 4th highest of 10, against a peer median of +2.1%.
- Total liabilities amounts to 87.8% of total assets for AMGN, versus a peer median of 67.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $141B USD | +2.7% | +4.1% | 104.3% | |
| Sep 2026 | $115.9B USD | +2.1% | +2.1% | 58.7% | |
| Jun 2026 | $115.64B USD | -1.2% | +6.2% | 57.5% | |
| Jun 2026 | $108.4B USD | +31.3% | +30.4% | 76.2% | |
| Jun 2026 | $87.82B USD | +28.3% | +10.1% | 67.7% | |
| Jun 2026 | $83.95B USD | +4.3% | +10.1% | 87.8% | |
| Jun 2026 | $80.09B USD | +28.5% | +6.0% | 65.6% | |
| Sep 2026 | $67.99B USD | -0.7% | +3.2% | 56.8% | |
| Jun 2026 | $65.32B USD | -15.4% | +2.9% | 74.5% | |
| Jun 2026 | £44.29B GBP | -28.0% | -3.5% | 72.2% | |
| Peer median (excluding AMGN) | — | +2.1% | +4.1% | 67.7% | |
Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.99B | 7.63B | 10.94B | 11.97B | 9.13B |
| Short-term Investments | 48M | 1.68B | 0 | 0 | 0 |
| Net Receivables | 5.84B | 6.39B | 7.94B | 7.5B | 9.57B |
| Inventory | 4.09B | 4.93B | 9.52B | 7B | 6.23B |
| Other Current Assets | 200M | 355M | 281M | 419M | 4.13B |
| Total Current Assets | 19.39B | 22.19B | 30.33B | 29.03B | 29.06B |
| Property, Plant & Equipment (Net) | 5.18B | 5.43B | 5.94B | 6.54B | 8.52B |
| Goodwill | 14.89B | 15.53B | 18.63B | 18.64B | 18.68B |
| Intangible Assets | 15.18B | 16.08B | 32.64B | 27.7B | 22.28B |
| Long-term Investments | 0 | 0 | 4.71B | 5.36B | 6.8B |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.52B | 5.9B | 4.9B | 4.58B | 5.25B |
| Total Non-current Assets | 41.78B | 42.94B | 66.82B | 62.81B | 61.53B |
| Total Assets | 61.17B | 65.12B | 97.15B | 91.84B | 90.59B |
| Account Payables | 1.37B | 1.57B | 1.59B | 1.91B | 2.37B |
| Short-term Debt | 87M | 1.59B | 1.44B | 3.55B | 4.6B |
| Tax Payables | 701M | 1.2B | 1.66B | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.62B | 1.1B | 1.38B | 1.33B | 1.44B |
| Total Current Liabilities | 12.18B | 15.69B | 18.39B | 23.1B | 25.49B |
| Long-term Debt | 33.22B | 37.35B | 63.17B | 56.55B | 50.01B |
| Deferred Tax Liabilities | 0 | 11M | 2.35B | 1.62B | 1.37B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 9.06B | 8.41B | 7.01B | 4.7B | 5.07B |
| Total Non-current Liabilities | 42.28B | 45.77B | 72.53B | 62.86B | 56.44B |
| Total Liabilities | 54.47B | 61.46B | 90.92B | 85.96B | 81.93B |
| Common Stock | 32.1B | 32.51B | 33.07B | 33.53B | 34.02B |
| Retained Earnings | (24.6B) | (28.62B) | (26.55B) | (27.59B) | (25.11B) |
| Accumulated OCI | (796M) | (231M) | (289M) | (66M) | (258M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 6.7B | 3.66B | 6.23B | 5.88B | 8.66B |
| Total Debt | 33.31B | 38.95B | 64.61B | 60.1B | 54.6B |
| Net Debt | 25.32B | 31.32B | 53.67B | 48.13B | 45.48B |
Amgen Inc.
NASDAQ:AMGN
Intrinsic Alpha fair value
Locked
Current Price
$443.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.